Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 51: 138-143, 2005. First published November 18, 2004; 10.1373/clinchem.2004.035923
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2004.035923v1
51/1/138    most recent
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (9)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hermann-Arnhof, K.-M.
Right arrow Articles by Köller, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hermann-Arnhof, K.-M.
Right arrow Articles by Köller, U.
Related Collections
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2005;51:138-143.)
© 2005 American Association for Clinical Chemistry, Inc.

Lipids, Lipoproteins, and Cardiovascular Risk Factors

N-Terminal Pro-B-Type Natriuretic Peptide as an Indicator of Possible Cardiovascular Disease in Severely Obese Individuals: Comparison with Patients in Different Stages of Heart Failure

Katharina-Maria Hermann-Arnhof1,a, Ursula Hanusch-Enserer4, Thomas Kaestenbauer2, Thomas Publig3, Attila Dunky4, Harald R. Rosen5, Rudolf Prager2 and Ursula Köller1

1 Department for Clinical and Chemical Laboratory Diagnostic, 2 Ludwig Bolzmann Institute for Metabolic Diseases and Nutrition and Department of Internal Medicine III, Division of Metabolic Diseases and Nephrology, and 3 Department of Internal Medicine IV, Division of Cardiology, Hospital Lainz, Vienna, Austria.
4 Department of Internal Medicine V, Division of Diabetology and Rheumatology, Wilhelminenspital, Vienna, Austria.
5 Department of Surgery, SMZO, Vienna, Austria.

aAddress correspondence to this author at: Institute for Medical and Chemical Laboratory Diagnostics, Hospital Lainz, Wolkersbergenstrasse 1, 1130 Vienna, Austria. Fax 43-1-80110/2688; e-mail katharina.hermann{at}wienkav.at.

Background: Mild stages of heart failure might be difficult to diagnose in severely obese individuals with a body mass index (BMI) >40 kg/m2. Measurement of the N-terminal fragment of pro-B-type natriuretic peptide (NT-proBNP) is feasible for detecting cardiac impairment. The aims of our study were to measure NT-proBNP in plasma of severely obese patients and to compare the results with results for patients in different stages of manifest cardiac dysfunction.

Methods: In 61 severely obese individuals (median BMI, 43.2 kg/m2) and 96 nonobese patients with existing heart failure [classified into New York Heart Association (NYHA) classes I–IV], NT-proBNP was measured in the fasting condition. A medical history, physical examination, electrocardiography, blood chemistry, and chest x-ray were performed in the obese group. In addition, echocardiography was performed in the NYHA group.

Results: In obese individuals, NT-proBNP was increased to a median of 356 (interquartile range, 221–458) pmol/L [854 (530–1099) ng/L] and was comparable (P >0.05) to the median value for NYHA I patients {289 (258–451) pmol/L [694 (619–1082) ng/L]}, but was significantly lower than in the other NYHA groups (P <0.001 for each).

Conclusion: The prognostic relevance of increased NT-proBNP for risk of developing cardiac insufficiency in severely obese patients needs to be further evaluated.




The following articles in journals at HighWire Press have cited this article:


Home page
 CirculationHome page
F. S. Apple, A. H.B. Wu, A. S. Jaffe, M. Panteghini, R. H. Christenson, NACB COMMITTEE MEMBERS, R. H. Christenson, F. S. Apple, C. P. Cannon, G. Francis, et al.
National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical Issues for Biomarkers of Heart Failure
Circulation, July 31, 2007; 116(5): e95 - e98.
[Full Text] [PDF]

Home page
 J CARDIOVASC PHARMACOL THERHome page
R. Carrillo-Jimenez, S. Borzak, and C. H. Hennekens
Brain Natriuretic Peptide: Clinical and Research Challenges
Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2007; 12(2): 85 - 88.
[Abstract] [PDF]

Home page
 Clin. Chem.Home page
A. E. Malavazos, L. Morricone, A. Marocchi, F. Ermetici, B. Ambrosi, and M. M. Corsi
N-terminal pro-B-type natriuretic Peptide and echocardiographic abnormalities in severely obese patients: correlation with visceral fat.
Clin. Chem., June 1, 2006; 52(6): 1211 - 1213.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
J. V. St. Peter, G. G. Hartley, M. M. Murakami, and F. S. Apple
B-Type Natriuretic Peptide (BNP) and N-Terminal Pro-BNP in Obese Patients without Heart Failure: Relationship to Body Mass Index and Gastric Bypass Surgery
Clin. Chem., April 1, 2006; 52(4): 680 - 685.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Association for Clinical Chemistry.